BRPI0907530A2 - Anticorpos direcionados à angiopoietina-1 angiopoietina-2 e seus usos - Google Patents
Anticorpos direcionados à angiopoietina-1 angiopoietina-2 e seus usosInfo
- Publication number
- BRPI0907530A2 BRPI0907530A2 BRPI0907530-5A BRPI0907530A BRPI0907530A2 BR PI0907530 A2 BRPI0907530 A2 BR PI0907530A2 BR PI0907530 A BRPI0907530 A BR PI0907530A BR PI0907530 A2 BRPI0907530 A2 BR PI0907530A2
- Authority
- BR
- Brazil
- Prior art keywords
- angiopoietin
- antibodies directed
- antibodies
- directed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6663208P | 2008-02-20 | 2008-02-20 | |
| US61/066,632 | 2008-02-20 | ||
| US6194308P | 2008-06-16 | 2008-06-16 | |
| US61/061,943 | 2008-06-16 | ||
| US13936108P | 2008-12-19 | 2008-12-19 | |
| US61/139,361 | 2008-12-19 | ||
| PCT/US2009/001122 WO2009105269A1 (en) | 2008-02-20 | 2009-02-20 | Antibodies directed to angiopoietin-1 and angiopoietin-2 and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0907530A2 true BRPI0907530A2 (pt) | 2015-07-28 |
| BRPI0907530B1 BRPI0907530B1 (pt) | 2021-09-28 |
Family
ID=40625974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0907530-5A BRPI0907530B1 (pt) | 2008-02-20 | 2009-02-20 | Anticorpos monoclonais isolados, fragmentos de ligação ao antígeno e composições farmacêuticas |
Country Status (31)
| Country | Link |
|---|---|
| US (5) | US8030025B2 (pt) |
| EP (2) | EP2252632B1 (pt) |
| JP (1) | JP5739163B2 (pt) |
| KR (1) | KR101600639B1 (pt) |
| CN (1) | CN102046657B (pt) |
| AR (1) | AR070453A1 (pt) |
| AU (1) | AU2009215804B2 (pt) |
| BR (1) | BRPI0907530B1 (pt) |
| CA (2) | CA2844188A1 (pt) |
| CL (1) | CL2009000379A1 (pt) |
| CO (1) | CO6290772A2 (pt) |
| CR (1) | CR11658A (pt) |
| CY (1) | CY1115321T1 (pt) |
| DK (1) | DK2252632T3 (pt) |
| EA (1) | EA022308B1 (pt) |
| ES (2) | ES2660381T3 (pt) |
| HR (1) | HRP20140341T1 (pt) |
| IL (1) | IL207445A (pt) |
| JO (1) | JO2913B1 (pt) |
| MA (1) | MA32190B1 (pt) |
| MX (1) | MX2010009185A (pt) |
| MY (1) | MY156458A (pt) |
| NZ (2) | NZ600112A (pt) |
| PE (1) | PE20091571A1 (pt) |
| PL (1) | PL2252632T3 (pt) |
| PT (1) | PT2252632E (pt) |
| RS (1) | RS53262B (pt) |
| SI (1) | SI2252632T1 (pt) |
| TW (1) | TWI433683B (pt) |
| WO (1) | WO2009105269A1 (pt) |
| ZA (1) | ZA201006173B (pt) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
| EA021967B1 (ru) | 2008-01-03 | 2015-10-30 | Дзе Скриппс Рисерч Инститьют | Доставка антител посредством модульного домена распознавания |
| US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
| US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
| US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
| JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| US8133979B2 (en) | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
| DE102009053584A1 (de) * | 2009-11-17 | 2011-05-19 | Airbus Operations Gmbh | Trägersystem zum Aufnehmen von Behältern in einem Fahrzeug und Verwendung eines Trägersystems in einem Flugzeug |
| WO2011140254A1 (en) * | 2010-05-04 | 2011-11-10 | Adimab, Llc | Antibodies against epidermal growth factor receptor (egfr) and uses thereof |
| WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| US9512220B2 (en) * | 2011-04-05 | 2016-12-06 | Neopharm Co., Ltd. | Antibodies against angiopoietins 1 and 2, and their use |
| DK2714738T3 (en) | 2011-05-24 | 2019-01-28 | Zyngenia Inc | MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS |
| US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
| DK2760471T3 (en) | 2011-09-30 | 2017-05-08 | Dana Farber Cancer Inst Inc | THERAPEUTIC PEPTIDES |
| US20130330745A1 (en) * | 2011-12-20 | 2013-12-12 | Abbott Japan Co. Ltd. | Methods of prognosis and diagnosis in sepsis |
| AU2013230750B2 (en) * | 2012-03-08 | 2018-02-01 | Medimmune, Llc | Methods of treatment with Angiopoietin-2 antibodies |
| SI3495387T1 (sl) | 2012-07-13 | 2021-12-31 | Roche Glycart Ag | Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| US10293023B2 (en) | 2013-03-15 | 2019-05-21 | Children's Medical Center Corporation | Method of altering vascular permeability and uses thereof |
| WO2014144817A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Inhibitory polypeptides specific to wnt inhibitors |
| WO2014144791A2 (en) | 2013-03-15 | 2014-09-18 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
| MX2015013163A (es) | 2013-03-15 | 2016-04-04 | Zyngenia Inc | Complejos multiespecificos multivalente y monovalentes y sus usos. |
| JP6469644B2 (ja) | 2013-03-15 | 2019-02-13 | アムジエン・インコーポレーテツド | 抗ｃｃｒ７抗原結合タンパク質に関係する方法および組成物 |
| US9902767B2 (en) | 2013-07-29 | 2018-02-27 | Samsung Electronics Co., Ltd. | Method of blocking vascular leakage using an anti-ANG2 antibody |
| KR102146845B1 (ko) | 2013-07-30 | 2020-08-21 | 삼성전자주식회사 | 앤지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도 |
| EP3712166A1 (en) | 2013-09-05 | 2020-09-23 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
| KR102196450B1 (ko) | 2013-09-17 | 2020-12-30 | 삼성전자주식회사 | Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제 |
| MX371187B (es) | 2013-12-06 | 2020-01-22 | Dana Farber Cancer Inst Inc | Péptidos terapéuticos. |
| KR102206029B1 (ko) * | 2014-01-27 | 2021-01-20 | 삼성전자주식회사 | Ang-2에 특이적으로 결합하는 항체 및 그의 용도 |
| EP3116903A2 (en) | 2014-03-14 | 2017-01-18 | Dana-Farber Cancer Institute, Inc. | Vaccine compositions and methods for restoring nkg2d pathway function against cancers |
| MA39599A (fr) | 2014-05-14 | 2016-10-05 | Merrimack Pharmaceuticals Inc | Dosage et administration d'agents thérapeutiques anti-egfr |
| WO2015175861A1 (en) | 2014-05-16 | 2015-11-19 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
| US9994632B2 (en) | 2014-05-26 | 2018-06-12 | Samsung Electronics Co., Ltd. | Humanized or affinity-matured anti Ang-2 antibody and uses thereof |
| US9719135B2 (en) * | 2014-07-03 | 2017-08-01 | Mannin Research Inc. | Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system |
| WO2016054114A1 (en) * | 2014-09-29 | 2016-04-07 | The Regents Of The University Of California | Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions |
| EP3207059A1 (en) | 2014-10-17 | 2017-08-23 | Amgen Inc. | Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies |
| WO2016075035A1 (en) * | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | Anti-ang2 antibodies and methods of use |
| US10857229B2 (en) | 2015-04-30 | 2020-12-08 | Amgen Inc. | Treatment of ovarian cancer in patients with ascites using a specific binding agent of human angiopoietin-2 in combination with a taxane |
| WO2016209972A1 (en) | 2015-06-26 | 2016-12-29 | Amgen Inc. | Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor |
| WO2018114728A1 (en) | 2016-12-20 | 2018-06-28 | F. Hoffmann-La Roche Ag | Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody |
| EP3565839A4 (en) | 2017-01-05 | 2021-04-21 | Gensun Biopharma Inc. | CHECKPOINT REGULATOR ANTAGONISTS |
| AU2018235928B2 (en) | 2017-03-14 | 2023-09-21 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
| US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
| WO2019028012A2 (en) | 2017-07-31 | 2019-02-07 | Dana-Farber Cancer Institute, Inc. | METHODS OF USING PEMBROLIZUMAB AND TREBANANIB |
| CN111699004A (zh) | 2018-02-06 | 2020-09-22 | 豪夫迈·罗氏有限公司 | 眼科疾病的治疗 |
| US12325737B2 (en) | 2018-03-26 | 2025-06-10 | Amgen Inc. | Total afucosylated glycoforms of antibodies produced in cell culture |
| JP2021529557A (ja) | 2018-06-29 | 2021-11-04 | ジェンサン バイオファーマ、 インコーポレイテッドＧｅｎｓｕｎ Ｂｉｏｐｈａｒｍａ， Ｉｎｃ． | 抗腫瘍免疫チェックポイント調節因子アンタゴニスト |
| CN119033684A (zh) | 2018-10-29 | 2024-11-29 | 豪夫迈·罗氏有限公司 | 抗体制剂 |
| EP3990116A1 (en) | 2019-06-28 | 2022-05-04 | Gensun Biopharma Inc. | ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD |
| JP7447144B2 (ja) * | 2019-08-14 | 2024-03-11 | ファームアブシン・インコーポレイテッド | 抗ｔｉｅ２抗体及びその用途 |
| KR20220069982A (ko) | 2019-09-26 | 2022-05-27 | 암젠 인크 | 항체 조성물의 생산 방법 |
| EP4045515A4 (en) | 2019-10-18 | 2023-10-18 | The Regents Of The University Of Michigan | BIOMATERIAL SENSOR SYSTEMS |
| WO2021247892A1 (en) | 2020-06-04 | 2021-12-09 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
| CN116472285A (zh) * | 2020-08-07 | 2023-07-21 | 南京金斯瑞生物科技有限公司 | 针对人血管生成素-2的抗体及其用途 |
| CN112126671B (zh) * | 2020-08-18 | 2021-08-31 | 中山大学附属第五医院 | 无乳链球菌Streptococus agalactiae治疗子宫内膜异位症的应用 |
| US20240043501A1 (en) | 2020-10-15 | 2024-02-08 | Amgen Inc. | Relative unpaired glycans in antibody production methods |
| JP2023548866A (ja) | 2020-10-29 | 2023-11-21 | インダストリアル ポリマーズ アンド ケミカルズ， インコーポレイテッド | 病原体監視及び不活性化のエアフィルター |
| EP4328242A4 (en) * | 2021-04-23 | 2025-07-16 | Neortesbio Inc | ANTIBODY SPECIFICALLY BINDING TO ANGIOPOIETIN-2 OR FRAGMENT THEREOF |
| CN117279940A (zh) * | 2021-04-23 | 2023-12-22 | 尼奥特思生物股份有限公司 | 与血管生成素-2特异性结合的抗体或其片段 |
| US20220389120A1 (en) | 2021-06-03 | 2022-12-08 | Gensun Biopharma Inc. | Multispecific antagonists |
| AU2022289365A1 (en) | 2021-06-07 | 2023-12-14 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
| WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| CN115947818B (zh) * | 2022-10-25 | 2024-08-02 | 福州大学 | 一种血管生成素1突变体的设计及其制备方法和应用 |
| JP2026516670A (ja) | 2023-04-20 | 2026-05-26 | アムジエン・インコーポレーテツド | 相対的な不対グリカン含有量を決定する方法 |
| AU2024325342A1 (en) | 2023-08-14 | 2026-02-26 | Amgen Inc. | Methods for reducing yellow color |
| WO2025101820A1 (en) | 2023-11-08 | 2025-05-15 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2026090253A1 (en) | 2024-10-23 | 2026-04-30 | Amgen Inc. | Methods of determining glycan pairing content |
Family Cites Families (196)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8925590D0 (en) | 1989-11-13 | 1990-01-04 | Central Blood Lab Authority | Monoclonal antibodies |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5889157A (en) | 1990-10-12 | 1999-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Humanized B3 antibody fragments, fusion proteins, and uses thereof |
| US5608039A (en) | 1990-10-12 | 1997-03-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Single chain B3 antibody fusion proteins and their uses |
| US5981726A (en) | 1990-10-12 | 1999-11-09 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and mutationally stabilized tumor-specific B1, B3 and B5 antibody fragments; immunotoxic fusion proteins; and uses thereof |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| PT528767E (pt) | 1991-08-21 | 2000-06-30 | Novartis Ag | Derivados de anticorpos |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5621083A (en) | 1991-11-04 | 1997-04-15 | Xoma Corporation | Immunotoxins comprising ribosome-inactivating proteins |
| US5837491A (en) | 1991-11-04 | 1998-11-17 | Xoma Corporation | Polynucleotides encoding gelonin sequences |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| WO1993011794A1 (en) | 1991-12-13 | 1993-06-24 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| US5955291A (en) | 1992-01-09 | 1999-09-21 | Alitalo; Kari | Antibodies recognizing tie receptor tyrosine kinase and uses thereof |
| US5811517A (en) | 1992-01-27 | 1998-09-22 | Icos Corporation | ICAM-related protein variants |
| US5837822A (en) | 1992-01-27 | 1998-11-17 | Icos Corporation | Humanized antibodies specific for ICAM related protein |
| US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
| DE69332197T2 (de) | 1992-03-13 | 2003-04-17 | Organon Teknika B.V., Boxtel | Epstein-Barr-Virus verwandte Peptide und Nukleinsäuresegmenten |
| ATE311895T1 (de) | 1992-05-26 | 2005-12-15 | Immunex Corp | Neue zytokine die cd30 binden |
| AU4651893A (en) | 1992-06-26 | 1994-01-24 | Immunex Corporation | Novel tyrosine kinase |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6066718A (en) | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
| JPH06153984A (ja) | 1992-11-27 | 1994-06-03 | Morinaga & Co Ltd | 抗体および抗体ｃＤＮＡ |
| US5750106A (en) | 1993-01-28 | 1998-05-12 | Novartis Ag | Human monoclonal antibodies to cytomegalovirus |
| WO1995013387A1 (en) | 1993-11-12 | 1995-05-18 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Tie-2, a novel receptor tyrosine kinase |
| US5643755A (en) | 1994-10-07 | 1997-07-01 | Regeneron Pharmaceuticals Inc. | Nucleic acid encoding tie-2 ligand |
| US5879672A (en) | 1994-10-07 | 1999-03-09 | Regeneron Pharmaceuticals, Inc. | Tie-2 ligand 1 |
| AUPM379494A0 (en) | 1994-02-10 | 1994-03-03 | Ludwig Institute For Cancer Research | Immunointeractive molecules - ii |
| US5650490A (en) | 1994-10-07 | 1997-07-22 | Regeneron Pharmaceuticals, Inc. | Tie-2 ligand 2 |
| US5814464A (en) | 1994-10-07 | 1998-09-29 | Regeneron Pharma | Nucleic acids encoding TIE-2 ligand-2 |
| AU717611B2 (en) | 1994-10-28 | 2000-03-30 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Tumor-specific antibody fragments, fusion proteins, and uses thereof |
| US5783184A (en) | 1994-12-23 | 1998-07-21 | Smithkline Beecham Corporation | Method for treatment and diagnosis of IL-5 mediated disorders |
| US20050287630A1 (en) | 1995-04-27 | 2005-12-29 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1997000271A1 (en) | 1995-06-14 | 1997-01-03 | The Regents Of The University Of California | Novel high affinity human antibodies to tumor antigens |
| EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
| AU2527397A (en) | 1996-03-13 | 1997-10-01 | Protein Design Labs, Inc. | Fas ligand fusion proteins and their uses |
| IL118626A0 (en) | 1996-06-11 | 1996-10-16 | Xtl Biopharmaceuticals Limited | Anti HBV antibody |
| US6265564B1 (en) | 1996-08-02 | 2001-07-24 | Regeneron Pharmaceuticals, Inc. | Expressed ligand-vascular intercellular signalling molecule |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| CA2264968A1 (en) | 1996-09-02 | 1998-03-12 | Ko Okumura | Humanized immunoglobulin reacting specifically with fas ligand or active fragments thereof and region inducing apoptosis originating in fas ligand |
| US5977319A (en) | 1996-10-21 | 1999-11-02 | Cambridge Antibody Technology Limited | Specific binding members for estradiol; materials and methods |
| WO1998018914A1 (en) | 1996-10-31 | 1998-05-07 | Duke University | Soluble tie2 receptor |
| US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| WO1998039027A2 (en) | 1997-03-05 | 1998-09-11 | John Wayne Cancer Institute | Sialyl lewis antigens as targets for immunotherapy |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| US5972338A (en) | 1997-09-19 | 1999-10-26 | Genentech, Inc. | Tie ligands homologues |
| US6030831A (en) | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
| US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| GB9804121D0 (en) | 1998-02-26 | 1998-04-22 | Cancer Res Campaign Tech | Anti-angiogenic vaccines: materials and methods relating thereto |
| WO1999045959A1 (en) | 1998-03-13 | 1999-09-16 | Dana-Farber Cancer Institute, Inc. | Humanized antibody and uses thereof |
| JP2000080100A (ja) | 1998-06-17 | 2000-03-21 | Japan Tobacco Inc | 副甲状腺ホルモン関連タンパクに対するヒトモノクローナル抗体 |
| US6387663B1 (en) | 1998-07-31 | 2002-05-14 | University Of Southern California | Targeting pharmaceutical agents to injured tissues |
| BR9915543A (pt) | 1998-10-16 | 2001-08-14 | Fraunhofer Ges Forschung | Resistência a doenças por plantas mediada por patogenicidas moleculares |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US7112661B1 (en) | 1998-10-30 | 2006-09-26 | The Research Foundation Of State University Of New York | Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha |
| ATE329263T1 (de) | 1998-10-30 | 2006-06-15 | Jonathan L Miller | Regionen variabler schwerer ketten und variabler leichter ketten von antikörpern für humanes blutplättchen-glykoprotein ib alpha |
| ES2706547T3 (es) | 1998-12-23 | 2019-03-29 | Pfizer | Anticuerpos monoclonales humanos para CTLA-4 |
| US6455035B1 (en) | 1999-03-26 | 2002-09-24 | Regeneron Pharmaceuticals, Inc. | Angiopoietins and methods of use thereof |
| NZ514434A (en) | 1999-03-26 | 2003-11-28 | Univ California | Modulation of vascular permeability by means of TIE2 receptor activators |
| DE10027695A1 (de) | 1999-05-27 | 2001-04-19 | Max Delbrueck Centrum | Vakzine gegen konformationsabhängige Antigene sowie gegen Antigene, die keine oder nicht ausschließlich Proteine oder Peptide sind |
| NZ516258A (en) | 1999-06-07 | 2004-02-27 | Immunex Corp | Tek antagonists |
| JP2003529324A (ja) | 1999-06-15 | 2003-10-07 | ジェネンテック・インコーポレーテッド | 分泌及び膜貫通ポリペプチドとそれをコードする核酸 |
| WO2001027279A1 (en) | 1999-10-12 | 2001-04-19 | Cambridge Antibody Technology | Human anti-adipocyte monoclonal antibodies and their use |
| JP2001206899A (ja) | 1999-11-18 | 2001-07-31 | Japan Tobacco Inc | ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途 |
| DE60035434T2 (de) | 1999-12-27 | 2008-05-15 | Crucell Holland B.V. | Auswahl von epitop-bindungsfähigen verbindungen aus bibliotheken |
| AU2001233277B2 (en) | 2000-02-03 | 2004-06-03 | Millennium Pharmaceuticals, Inc. | Humanized anti-ccr2 antibodies and methods of use therefor |
| US20020048763A1 (en) | 2000-02-04 | 2002-04-25 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis |
| EP1290217A2 (en) | 2000-02-04 | 2003-03-12 | Aeomica, Inc. | Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence |
| EP1130030A1 (en) | 2000-03-02 | 2001-09-05 | Roche Diagnostics Corporation | Human erythroid differentiation related factor |
| JP4019615B2 (ja) * | 2000-03-10 | 2007-12-12 | 富士ゼロックス株式会社 | 光磁気素子、光磁気ヘッドおよび磁気ディスク装置 |
| WO2001075110A2 (en) | 2000-03-30 | 2001-10-11 | Dyax Corp. | Mucin-1 specific binding members and methods of use thereof |
| US20010046496A1 (en) | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
| EP1156062A1 (en) | 2000-05-12 | 2001-11-21 | GPC Biotech AG | Immunomodulatory human MHC class II antigen-binding peptides/proteins |
| US7220840B2 (en) | 2000-06-16 | 2007-05-22 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator protein |
| AU2001268427B2 (en) | 2000-06-16 | 2007-03-29 | Glaxosmithkline Intellectual Property Limited | Antibodies that immunospecifically bind to blys |
| US20030166160A1 (en) | 2001-09-06 | 2003-09-04 | Hawley Stephen B. | Compounds and molecular complexes comprising multiple binding regions directed to transcytotic ligands |
| IL155204A0 (en) | 2000-10-02 | 2003-11-23 | Arizeke Pharmaceuticals Inc | Compositions and methods for the transport of biologically active agents across cellular barriers |
| EP1661986A1 (en) | 2000-11-17 | 2006-05-31 | Nuvelo, Inc. | Nucleic acids and polypeptides enocoded thereby that are member of the kallikrein gene familyNovel nucleic acids and polypeptides |
| DE10059930A1 (de) | 2000-11-23 | 2002-05-29 | Fischer Peter | Mittel humanen Ursprungs zur Vakzination gegen GD2-pos. Tumore |
| PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| WO2002055738A2 (en) | 2001-01-12 | 2002-07-18 | Incyte Genomics Inc | Molecules for disease detection and treatment |
| ATE425187T1 (de) | 2001-01-12 | 2009-03-15 | Molecules Of Man Ab | Materialien und methoden zur behandlung von hepatitis c |
| US20040219542A1 (en) | 2001-02-02 | 2004-11-04 | L.L. Houston | Compositions and methods for identifying, characterizing, optimizing and using ligands to transcytotic molecules |
| WO2002084277A1 (en) | 2001-04-17 | 2002-10-24 | Abmaxis, Inc. | Structure-based construction of human antibody library |
| CA2658221C (en) | 2001-04-27 | 2012-11-27 | Kyowa Kirin Co., Ltd. | Anti-cd40 monoclonal antibody |
| WO2002094864A2 (en) | 2001-05-25 | 2002-11-28 | Genset S.A. | Human cdnas and proteins and uses thereof |
| WO2003002608A1 (fr) | 2001-06-28 | 2003-01-09 | Kyowa Hakko Kogyo Co., Ltd. | Anticorps humanise contre le facteur-8 de croissance des fibroblastes et fragment de cet anticorps |
| CA2456121A1 (en) | 2001-08-03 | 2003-02-20 | Medical Research Council | Intracellular antibodies |
| US20050260195A1 (en) | 2001-10-04 | 2005-11-24 | Xtl Biopharmaceuticals Ltd. | Treatment of hepatitis B virus infection with human monoclonal antibodies |
| US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
| US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| AR036833A1 (es) | 2001-10-18 | 2004-10-06 | Bayer Corp | Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular. |
| AU2002335085A1 (en) | 2001-10-25 | 2003-05-06 | Regeneron Pharmaceuticals, Inc. | Angiopoietins and methods of use thereof |
| EP1537140B1 (en) | 2001-11-07 | 2013-01-02 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US7365167B2 (en) | 2001-11-26 | 2008-04-29 | Cell Matrix, Inc. | Humanized collagen antibodies and related methods |
| US7390885B2 (en) | 2001-11-26 | 2008-06-24 | Cell Matrix, Inc. | Humanized collagen antibodies and related methods |
| JP4723810B2 (ja) | 2001-12-03 | 2011-07-13 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | ハイブリッド抗体 |
| AU2002351208A1 (en) | 2001-12-03 | 2003-06-17 | Abgenix, Inc. | Antibodies against carbonic anhydrase IX (CA IX) tumor antigen |
| AR037756A1 (es) | 2001-12-17 | 2004-12-01 | Bayer Corp | Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma. |
| CA2471938A1 (en) | 2001-12-28 | 2003-07-17 | Kyowa Hakko Kogyo Co., Ltd. | Agent for treating arthritis |
| EP1470146B8 (en) | 2001-12-28 | 2007-09-12 | Amgen Fremont Inc. | Antibodies against the muc18 antigen |
| JP2005514409A (ja) | 2001-12-28 | 2005-05-19 | アブジェニックス・インコーポレーテッド | Ｍｕｃ１８抗原に対する抗体の使用 |
| EP1467756A4 (en) | 2001-12-28 | 2007-03-21 | Abgenix Inc | METHODS OF USING ANTI-MUC18 ANTIBODIES |
| US7135174B2 (en) | 2002-01-07 | 2006-11-14 | Amgen Fremont, Inc. | Antibodies directed to PDGFD and uses thereof |
| US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| US7553485B2 (en) | 2002-01-18 | 2009-06-30 | Pierre Fabre Medicament | Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof |
| US20040258699A1 (en) | 2002-02-11 | 2004-12-23 | Bowdish Katherine S. | Immunotherapeutics for biodefense |
| AR038568A1 (es) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
| AU2003216341A1 (en) | 2002-02-20 | 2003-09-09 | Dyax Corporation | Mhc-peptide complex binding ligands |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
| ES2295639T3 (es) | 2002-06-13 | 2008-04-16 | Crucell Holland B.V. | Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion. |
| CA2491471A1 (en) | 2002-07-03 | 2004-01-15 | The Trustees Of The University Of Pennsylvania | Compositions, methods and kits relating to anti-platelet autoantibodies and inhibitors thereof |
| NZ537277A (en) | 2002-07-18 | 2008-04-30 | Crucell Holland Bv | Recombinant production of mixtures of antibodies |
| US20040110933A1 (en) | 2002-09-13 | 2004-06-10 | Dyax Corporation | CD44-binding ligands |
| US20040141969A1 (en) | 2002-09-16 | 2004-07-22 | Juergen Floege | Method for the treatment of nephritis using anti-PDGF-DD antibodies |
| AU2003284062A1 (en) | 2002-10-09 | 2004-05-04 | Integrigen, Inc. | Recombinant catalytic polypeptides and their uses |
| US20040151724A1 (en) | 2002-10-31 | 2004-08-05 | Julia Coronella-Wood | Antibody fab fragments specific for breast cancer |
| AU2003284427A1 (en) | 2002-11-22 | 2004-06-18 | Chugai Seiyaku Kabushiki Kaisha | Antibody against lesion tissue |
| DE10256900A1 (de) | 2002-11-29 | 2004-06-24 | Nemod Immuntherapie Ag | Tumorspezifische Erkennungsmoleküle |
| AU2003299581A1 (en) | 2002-12-02 | 2004-06-23 | Abgenix, Inc. | Antibodies against drugs of abuse |
| US20050058649A1 (en) | 2002-12-02 | 2005-03-17 | Landes Gregory M. | Antibodies directed to phospholipase A2 and uses thereof |
| JP4754219B2 (ja) | 2002-12-02 | 2011-08-24 | アムジエン・フレモント・インコーポレイテツド | 腫瘍壊死因子を対象とする抗体、およびそれらの使用 |
| US20050009136A1 (en) | 2003-02-19 | 2005-01-13 | Dyax Corporation | PAPP-A ligands |
| CA2519528C (en) | 2003-03-19 | 2016-01-26 | Abgenix, Inc. | Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof |
| DK1626992T3 (da) | 2003-05-23 | 2010-09-20 | Crucell Holland Bv | Produktion af rekombinant IgM i PER.C6-celler |
| TWI306458B (en) | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
| US7595379B2 (en) | 2003-05-30 | 2009-09-29 | Agensys, Inc. | Antibodies and related molecules that bind to PSCA proteins |
| MXPA05014155A (es) | 2003-06-27 | 2006-05-25 | Abgenix Inc | Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos. |
| AU2004260884B2 (en) | 2003-07-22 | 2009-11-19 | Crucell Holland B.V. | Binding molecules against SARS-coronavirus and uses thereof |
| US7318925B2 (en) | 2003-08-08 | 2008-01-15 | Amgen Fremont, Inc. | Methods of use for antibodies against parathyroid hormone |
| CN1838968A (zh) | 2003-08-08 | 2006-09-27 | 艾伯吉尼斯公司 | 针对甲状旁腺激素(pth)之抗体和其用途 |
| US7871610B2 (en) | 2003-08-12 | 2011-01-18 | Dyax Corp. | Antibodies to Tie1 ectodomain |
| US7485297B2 (en) | 2003-08-12 | 2009-02-03 | Dyax Corp. | Method of inhibition of vascular development using an antibody |
| EP1660537A2 (en) | 2003-08-14 | 2006-05-31 | Dyax Corp. | Endotheliase-2 ligands |
| EP1508576A1 (en) | 2003-08-20 | 2005-02-23 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
| SI1680140T1 (sl) | 2003-10-16 | 2011-08-31 | Imclone Llc | Inhibitorji receptorja-1 za fibroblastni rastni faktor in metode za zdravljenje z le-temi |
| AU2004287879C1 (en) | 2003-11-04 | 2011-05-26 | Novartis Vaccines And Diagnostics, Inc. | Antagonist anti-CD40 monoclonal antibodies and methods for their use |
| US20070098718A1 (en) | 2003-11-04 | 2007-05-03 | Chiron | Methods of therapy for b cell-related cancers |
| JP4637749B2 (ja) | 2003-11-11 | 2011-02-23 | 中外製薬株式会社 | ヒト化抗ｃｄ４７抗体 |
| US7612179B2 (en) | 2003-11-28 | 2009-11-03 | Astrazeneca Ab | antibodies binding to a C-terminal fragment of apoliopoprotein E |
| WO2005051998A2 (en) | 2003-11-28 | 2005-06-09 | Astrazeneca Ab | Antibodies binding to a c-terminal fragment of apolipoprotein e |
| EP1706425A2 (en) | 2003-12-05 | 2006-10-04 | John R. Schreiber | Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse® |
| TW200530269A (en) | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Anti-Mpl antibodies |
| US20050136055A1 (en) | 2003-12-22 | 2005-06-23 | Pfizer Inc | CD40 antibody formulation and methods |
| DOP2005000002A (es) | 2004-01-09 | 2005-08-15 | Pfizer | "anticuerpos contra madcam" |
| EP2915820A1 (en) | 2004-02-06 | 2015-09-09 | MorphoSys AG | Anti-CD38 human antibodies and uses therefor |
| TW200605906A (en) | 2004-05-11 | 2006-02-16 | Chugai Pharmaceutical Co Ltd | Remedy for thrombopenia |
| PL2314621T3 (pl) | 2004-05-27 | 2014-08-29 | Crucell Holland Bv | Cząsteczki wiążące zdolne do neutralizowania wirusa wścieklizny i ich zastosowania |
| US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| AU2005256113B2 (en) | 2004-07-09 | 2011-02-10 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody |
| JP2008505943A (ja) | 2004-07-14 | 2008-02-28 | イゲネーオン・クレープス−イムンテラピー・フォルシュングス−ウント・エントヴィックルングス−アクチェンゲゼルシャフト | グリコシル化抗体 |
| JP4926054B2 (ja) | 2004-07-20 | 2012-05-09 | シムフォゲン・アクティーゼルスカブ | 抗−ＲｈＤ組換えポリクローナル抗体及び製造方法 |
| WO2006037604A1 (en) | 2004-10-01 | 2006-04-13 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Novel antibodies directed to the mammalian eag1 ion channel protein |
| ZA200705695B (en) | 2004-12-21 | 2009-02-25 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
| MY146381A (en) * | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
| PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| US8359965B2 (en) | 2007-09-17 | 2013-01-29 | Oxford J Craig | Apparatus and method for broad spectrum radiation attenuation |
| JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| WO2009158432A2 (en) * | 2008-06-27 | 2009-12-30 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| US9100245B1 (en) | 2012-02-08 | 2015-08-04 | Amazon Technologies, Inc. | Identifying protected media files |
| WO2013180295A1 (ja) | 2012-06-01 | 2013-12-05 | 日本電信電話株式会社 | パケット転送処理方法およびパケット転送処理装置 |
| US9306926B2 (en) | 2013-03-15 | 2016-04-05 | Brian A. Truong | User authentication using unique hidden identifiers |
| US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
-
2009
- 2009-02-10 JO JO200963A patent/JO2913B1/en active
- 2009-02-19 PE PE2009000241A patent/PE20091571A1/es active IP Right Grant
- 2009-02-19 US US12/378,993 patent/US8030025B2/en active Active
- 2009-02-19 CL CL2009000379A patent/CL2009000379A1/es unknown
- 2009-02-20 AU AU2009215804A patent/AU2009215804B2/en active Active
- 2009-02-20 ES ES13185473.9T patent/ES2660381T3/es active Active
- 2009-02-20 HR HRP20140341AT patent/HRP20140341T1/hr unknown
- 2009-02-20 EA EA201001335A patent/EA022308B1/ru not_active IP Right Cessation
- 2009-02-20 JP JP2010547650A patent/JP5739163B2/ja active Active
- 2009-02-20 TW TW098105405A patent/TWI433683B/zh not_active IP Right Cessation
- 2009-02-20 MY MYPI2010003790A patent/MY156458A/en unknown
- 2009-02-20 NZ NZ600112A patent/NZ600112A/xx not_active IP Right Cessation
- 2009-02-20 SI SI200930856T patent/SI2252632T1/sl unknown
- 2009-02-20 KR KR1020107021162A patent/KR101600639B1/ko not_active Expired - Fee Related
- 2009-02-20 PT PT97118699T patent/PT2252632E/pt unknown
- 2009-02-20 EP EP09711869.9A patent/EP2252632B1/en active Active
- 2009-02-20 RS RS20140162A patent/RS53262B/sr unknown
- 2009-02-20 ES ES09711869.9T patent/ES2453342T3/es active Active
- 2009-02-20 DK DK09711869.9T patent/DK2252632T3/da active
- 2009-02-20 MX MX2010009185A patent/MX2010009185A/es active IP Right Grant
- 2009-02-20 WO PCT/US2009/001122 patent/WO2009105269A1/en not_active Ceased
- 2009-02-20 CA CA2844188A patent/CA2844188A1/en not_active Abandoned
- 2009-02-20 EP EP13185473.9A patent/EP2679599B1/en active Active
- 2009-02-20 CN CN200980114708.7A patent/CN102046657B/zh not_active Expired - Fee Related
- 2009-02-20 PL PL09711869T patent/PL2252632T3/pl unknown
- 2009-02-20 CA CA2715324A patent/CA2715324C/en active Active
- 2009-02-20 AR ARP090100593A patent/AR070453A1/es active IP Right Grant
- 2009-02-20 BR BRPI0907530-5A patent/BRPI0907530B1/pt not_active IP Right Cessation
- 2009-02-20 NZ NZ587230A patent/NZ587230A/xx not_active IP Right Cessation
-
2010
- 2010-08-05 IL IL207445A patent/IL207445A/en active IP Right Grant
- 2010-08-30 ZA ZA2010/06173A patent/ZA201006173B/en unknown
- 2010-08-30 CR CR11658A patent/CR11658A/es unknown
- 2010-09-01 CO CO10107938A patent/CO6290772A2/es active IP Right Grant
- 2010-09-13 MA MA33172A patent/MA32190B1/fr unknown
-
2011
- 2011-07-29 US US13/194,854 patent/US8221749B2/en active Active
-
2012
- 2012-06-15 US US13/524,325 patent/US20120258122A1/en not_active Abandoned
-
2013
- 2013-08-26 US US13/975,748 patent/US20130336992A1/en not_active Abandoned
-
2014
- 2014-02-13 CY CY20141100111T patent/CY1115321T1/el unknown
-
2016
- 2016-12-02 US US15/367,955 patent/US10336820B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3339323T (pt) | Anticorpos anti-péptido beta-amilóide n3pglu e seus usos | |
| DK2252632T3 (da) | Antistoffer rettet mod angiopoietin-1 og angiopoietin-2 og anvendelse heraf | |
| CY2017021I1 (el) | Υψηλης συναφειας ανθρωπινα αντισωματα προς pcsk9 | |
| BRPI1012321A2 (pt) | anticorpos anti-vegf e seus usos | |
| BRPI0906498A2 (pt) | Anticorpo ron e seus usos | |
| BRPI1010540A2 (pt) | "anticorpos especéficos para dkk-1 e seus usos" | |
| BR112013012132A2 (pt) | composição compreendendo proteínas e oligossacarídeos hidrolisados, e seus usos | |
| PT2473528E (pt) | Formulações estáveis de polipéptidos e seus usos | |
| BRPI0910746A2 (pt) | reticuladores e seus usos | |
| BR112013006272A2 (pt) | compostos de piridina e seus usos | |
| BRPI0913640A2 (pt) | substâncias policrômicas e seus usos | |
| BRPI0908177A2 (pt) | compósito elástico e método para produzir o mesmo | |
| BR112012010226A2 (pt) | artigo absorvente descartável com núcleo absorvente com perfil traçado | |
| BR112014009070A2 (pt) | método de síntese e intermediários úteis na preparação de pirrolobenzo-diazepinas | |
| BRPI1010533A2 (pt) | tetrahidroazolopirazinas sulfoniladas e seu uso como medicamentos | |
| BR112013012190A2 (pt) | composições adesivas e seus usos | |
| BR112013012129A2 (pt) | composições de adesivos e seus usos | |
| EP2486905A4 (en) | HIGH-DRAWN VOIDABLE ARTICLE | |
| BRPI0906387A2 (pt) | Anticorpos alfa 5 - beta 1 e seus usos | |
| PT3686183T (pt) | Fenilacetato de l-ornitina e métodos de preparação do mesmo | |
| BR112013023743A2 (pt) | anticorpo de fator de tecidos humanos e usos do mesmo | |
| BR112012003844A2 (pt) | vacinas de pttv e diagnóstico | |
| BRPI1016067A2 (pt) | ésteres e seus usos. | |
| BR112013033919A2 (pt) | combinações e seus usos | |
| BR112013008898A2 (pt) | benzamidas substituídas e seus usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/02/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 15A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2762 DE 12-12-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |